Aridis Pharmaceuticals Inc’s (ARDS) Lock-Up Period Set To End Tomorrow

Share on StockTwits

Aridis Pharmaceuticals’ (NASDAQ:ARDS) lock-up period is set to expire on Monday, February 11th. Aridis Pharmaceuticals had issued 2,000,000 shares in its public offering on August 14th. The total size of the offering was $26,000,000 based on an initial share price of $13.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Several brokerages have weighed in on ARDS. Maxim Group set a $25.00 price objective on Aridis Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 13th. Zacks Investment Research raised Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Tuesday, November 13th. Cantor Fitzgerald reissued a “buy” rating and set a $25.00 price objective on shares of Aridis Pharmaceuticals in a report on Tuesday, November 13th. Finally, ValuEngine lowered Aridis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $25.40.

NASDAQ:ARDS opened at $8.55 on Friday. Aridis Pharmaceuticals has a 1 year low of $7.59 and a 1 year high of $13.85.

Aridis Pharmaceuticals (NASDAQ:ARDS) last posted its earnings results on Tuesday, November 13th. The company reported ($1.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.92). The business had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $0.33 million. Sell-side analysts predict that Aridis Pharmaceuticals will post -4.2 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Aridis Pharmaceuticals Inc’s (ARDS) Lock-Up Period Set To End Tomorrow” was published by Macon Daily and is the property of of Macon Daily. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://macondaily.com/2019/02/10/aridis-pharmaceuticals-incs-ards-lock-up-period-set-to-end-tomorrow.html.

Aridis Pharmaceuticals Company Profile

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Further Reading: Coverage Ratio

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply